Share Price and Basic Stock Data
Last Updated: November 12, 2025, 9:14 pm
| PEG Ratio | -3.91 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Kopran Ltd operates within the pharmaceuticals industry, showcasing a consistent revenue trajectory over recent years. The company’s reported sales rose from ₹478 Cr in FY 2022 to ₹551 Cr in FY 2023, representing a growth rate of 15.3%. The sales for FY 2024 are projected to increase further to ₹615 Cr, indicating a continued upward trend. On a quarterly basis, Kopran’s sales fluctuated, with the highest quarterly sales recorded at ₹186.08 Cr in Q4 FY 2024, while the lowest was ₹116.97 Cr in Q2 FY 2023. This variability reflects seasonal influences and market dynamics. The trailing twelve months (TTM) revenue stood at ₹625 Cr, underscoring a robust performance. Despite challenges faced in the pharmaceutical sector, Kopran’s ability to generate revenue growth places it in a favorable position compared to many competitors in the industry.
Profitability and Efficiency Metrics
Kopran Ltd’s profitability metrics reveal a mixed performance, with the operating profit margin (OPM) standing at 10.45% in FY 2025, down from 18% in FY 2022. The decline in margin indicates rising costs, impacting profitability. The net profit for FY 2023 was reported at ₹27 Cr, with an EPS of ₹5.65, which improved to ₹39 Cr and an EPS of ₹7.99 in FY 2025. Interest coverage ratio (ICR) stood at 8.23x, reflecting a solid ability to meet interest obligations. The company’s return on equity (ROE) was reported at 7.64%, while the return on capital employed (ROCE) stood at 9.75%, both of which are relatively low compared to sector averages, indicating potential inefficiencies in capital utilization. However, the firm’s capability to generate operating profit, even in challenging environments, showcases a degree of resilience.
Balance Sheet Strength and Financial Ratios
Kopran Ltd’s balance sheet exhibits a stable structure, with total assets amounting to ₹844 Cr in FY 2025. The company’s reserves increased to ₹470 Cr, reflecting prudent financial management and the retention of earnings for future growth. Total borrowings stood at ₹148 Cr, indicating a manageable debt level with a debt-to-equity ratio of 0.28x, suggesting low leverage and financial risk. The current ratio of 1.76x indicates adequate liquidity to meet short-term obligations, while the quick ratio of 1.18x further supports this liquidity position. The price-to-book value (P/BV) ratio is reported at 1.63x, indicating that the stock may be trading at a reasonable valuation relative to its book value. Overall, the financial ratios suggest that Kopran maintains a solid balance sheet, though the profitability metrics indicate areas for improvement.
Shareholding Pattern and Investor Confidence
Kopran Ltd’s shareholding structure reflects a diverse base of investors, with promoters holding 44.43% of the equity as of September 2025. The public holds a significant 54.99% stake, while foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 0.60% and 0.00%, respectively. The increase in the number of shareholders from 42,034 in December 2022 to 62,222 in September 2025 indicates growing investor interest and confidence in the company. The consistency in promoter shareholding suggests stability in management control. However, the low institutional participation may highlight a lack of confidence among institutional players or perceived risks in the company’s performance. The dividend payout ratio for FY 2025 stood at 37.51%, reflecting a balanced approach to rewarding shareholders while retaining earnings for growth.
Outlook, Risks, and Final Insight
Looking forward, Kopran Ltd faces both opportunities and challenges. The pharmaceutical sector’s growth potential remains strong, driven by increasing healthcare demands. However, the company must navigate rising costs and competitive pressures that could affect margins. Key strengths include a solid balance sheet, a diverse shareholder base, and a history of revenue growth. Conversely, risks include operational inefficiencies reflected in low ROE and ROCE, as well as potential market volatility impacting sales. Should Kopran manage to improve its operational efficiency and expand its market presence, it could enhance profitability and shareholder value. Conversely, failure to address cost pressures may hinder growth and investor sentiment. The company’s future performance will depend on its ability to adapt to market conditions while leveraging its strengths.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Kopran Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 135 Cr. | 107 | 247/84.3 | 30.7 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,901 Cr. | 450 | 479/192 | 102 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.7 Cr. | 44.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 38.0 Cr. | 26.0 | 29.1/17.0 | 39.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,221.27 Cr | 1,192.93 | 53.76 | 199.56 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 125.62 | 116.97 | 158.00 | 148.88 | 117.00 | 152.59 | 158.92 | 186.08 | 139.44 | 151.56 | 166.24 | 172.36 | 135.22 |
| Expenses | 112.46 | 106.83 | 145.68 | 136.72 | 110.69 | 129.76 | 135.34 | 164.39 | 121.28 | 136.83 | 146.39 | 155.27 | 121.09 |
| Operating Profit | 13.16 | 10.14 | 12.32 | 12.16 | 6.31 | 22.83 | 23.58 | 21.69 | 18.16 | 14.73 | 19.85 | 17.09 | 14.13 |
| OPM % | 10.48% | 8.67% | 7.80% | 8.17% | 5.39% | 14.96% | 14.84% | 11.66% | 13.02% | 9.72% | 11.94% | 9.92% | 10.45% |
| Other Income | 0.65 | 0.44 | 2.22 | 3.78 | 2.39 | 0.13 | 2.43 | 9.67 | 2.63 | 1.00 | 0.17 | 3.26 | 2.56 |
| Interest | 0.79 | 1.28 | 2.24 | 1.78 | 1.83 | 1.94 | 2.24 | 2.59 | 2.18 | 2.23 | 2.16 | 2.77 | 2.54 |
| Depreciation | 3.05 | 3.25 | 3.16 | 3.24 | 3.26 | 2.77 | 3.27 | 3.59 | 3.87 | 3.85 | 4.00 | 3.87 | 4.26 |
| Profit before tax | 9.97 | 6.05 | 9.14 | 10.92 | 3.61 | 18.25 | 20.50 | 25.18 | 14.74 | 9.65 | 13.86 | 13.71 | 9.89 |
| Tax % | 23.77% | 23.14% | 23.96% | 26.37% | 22.99% | 24.55% | 23.02% | 26.01% | 24.69% | 23.42% | 24.96% | 29.39% | 24.67% |
| Net Profit | 7.60 | 4.65 | 6.95 | 8.04 | 2.77 | 13.77 | 15.79 | 18.62 | 11.10 | 7.38 | 10.40 | 9.68 | 7.45 |
| EPS in Rs | 1.58 | 0.96 | 1.44 | 1.67 | 0.57 | 2.86 | 3.28 | 3.86 | 2.30 | 1.53 | 2.16 | 2.01 | 1.54 |
Last Updated: August 1, 2025, 6:15 pm
Below is a detailed analysis of the quarterly data for Kopran Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 135.22 Cr.. The value appears to be declining and may need further review. It has decreased from 172.36 Cr. (Mar 2025) to 135.22 Cr., marking a decrease of 37.14 Cr..
- For Expenses, as of Jun 2025, the value is 121.09 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 155.27 Cr. (Mar 2025) to 121.09 Cr., marking a decrease of 34.18 Cr..
- For Operating Profit, as of Jun 2025, the value is 14.13 Cr.. The value appears to be declining and may need further review. It has decreased from 17.09 Cr. (Mar 2025) to 14.13 Cr., marking a decrease of 2.96 Cr..
- For OPM %, as of Jun 2025, the value is 10.45%. The value appears strong and on an upward trend. It has increased from 9.92% (Mar 2025) to 10.45%, marking an increase of 0.53%.
- For Other Income, as of Jun 2025, the value is 2.56 Cr.. The value appears to be declining and may need further review. It has decreased from 3.26 Cr. (Mar 2025) to 2.56 Cr., marking a decrease of 0.70 Cr..
- For Interest, as of Jun 2025, the value is 2.54 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.77 Cr. (Mar 2025) to 2.54 Cr., marking a decrease of 0.23 Cr..
- For Depreciation, as of Jun 2025, the value is 4.26 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.87 Cr. (Mar 2025) to 4.26 Cr., marking an increase of 0.39 Cr..
- For Profit before tax, as of Jun 2025, the value is 9.89 Cr.. The value appears to be declining and may need further review. It has decreased from 13.71 Cr. (Mar 2025) to 9.89 Cr., marking a decrease of 3.82 Cr..
- For Tax %, as of Jun 2025, the value is 24.67%. The value appears to be improving (decreasing) as expected. It has decreased from 29.39% (Mar 2025) to 24.67%, marking a decrease of 4.72%.
- For Net Profit, as of Jun 2025, the value is 7.45 Cr.. The value appears to be declining and may need further review. It has decreased from 9.68 Cr. (Mar 2025) to 7.45 Cr., marking a decrease of 2.23 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.54. The value appears to be declining and may need further review. It has decreased from 2.01 (Mar 2025) to 1.54, marking a decrease of 0.47.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:59 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 303 | 326 | 296 | 310 | 313 | 358 | 360 | 492 | 478 | 551 | 615 | 630 | 625 |
| Expenses | 260 | 294 | 266 | 274 | 283 | 312 | 313 | 410 | 390 | 499 | 540 | 557 | 560 |
| Operating Profit | 43 | 31 | 30 | 36 | 31 | 46 | 47 | 82 | 87 | 52 | 74 | 73 | 66 |
| OPM % | 14% | 10% | 10% | 12% | 10% | 13% | 13% | 17% | 18% | 9% | 12% | 12% | 11% |
| Other Income | 2 | -48 | 1 | 11 | 9 | 3 | -0 | 18 | 11 | 3 | 15 | 4 | 7 |
| Interest | 14 | 13 | 13 | 14 | 9 | 9 | 9 | 6 | 5 | 6 | 9 | 9 | 10 |
| Depreciation | 13 | 10 | 8 | 8 | 9 | 9 | 10 | 10 | 11 | 13 | 13 | 16 | 16 |
| Profit before tax | 17 | -39 | 11 | 25 | 23 | 32 | 28 | 83 | 82 | 36 | 68 | 52 | 47 |
| Tax % | 0% | 0% | 0% | 20% | 10% | 24% | 26% | 26% | 25% | 24% | 25% | 26% | |
| Net Profit | 17 | -39 | 11 | 20 | 20 | 24 | 21 | 62 | 61 | 27 | 51 | 39 | 35 |
| EPS in Rs | 4.40 | -9.52 | 2.48 | 4.60 | 4.74 | 5.55 | 4.86 | 14.24 | 12.66 | 5.65 | 10.57 | 7.99 | 7.24 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 21% | 24% | 53% | 28% | 38% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -329.41% | 128.21% | 81.82% | 0.00% | 20.00% | -12.50% | 195.24% | -1.61% | -55.74% | 88.89% | -23.53% |
| Change in YoY Net Profit Growth (%) | 0.00% | 457.62% | -46.39% | -81.82% | 20.00% | -32.50% | 207.74% | -196.85% | -54.12% | 144.63% | -112.42% |
Kopran Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 12% |
| 3 Years: | 10% |
| TTM: | -2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 12% |
| 3 Years: | -14% |
| TTM: | -41% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 18% |
| 3 Years: | -2% |
| 1 Year: | -51% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 12% |
| 3 Years: | 8% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 9:15 am
Balance Sheet
Last Updated: September 10, 2025, 1:58 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 39 | 41 | 43 | 43 | 43 | 43 | 43 | 43 | 48 | 48 | 48 | 48 |
| Reserves | 67 | 49 | 57 | 81 | 101 | 125 | 146 | 202 | 378 | 391 | 443 | 470 |
| Borrowings | 137 | 86 | 80 | 95 | 89 | 97 | 88 | 66 | 75 | 75 | 99 | 148 |
| Other Liabilities | 56 | 99 | 84 | 78 | 82 | 85 | 92 | 128 | 110 | 135 | 153 | 178 |
| Total Liabilities | 299 | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 611 | 650 | 743 | 844 |
| Fixed Assets | 105 | 102 | 101 | 104 | 104 | 113 | 111 | 112 | 151 | 165 | 182 | 208 |
| CWIP | 20 | 1 | 3 | 6 | 10 | 24 | 30 | 43 | 36 | 70 | 97 | 113 |
| Investments | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 174 | 172 | 160 | 187 | 201 | 214 | 229 | 284 | 425 | 415 | 465 | 522 |
| Total Assets | 299 | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 611 | 650 | 743 | 844 |
Below is a detailed analysis of the balance sheet data for Kopran Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 48.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 48.00 Cr..
- For Reserves, as of Mar 2025, the value is 470.00 Cr.. The value appears strong and on an upward trend. It has increased from 443.00 Cr. (Mar 2024) to 470.00 Cr., marking an increase of 27.00 Cr..
- For Borrowings, as of Mar 2025, the value is 148.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 99.00 Cr. (Mar 2024) to 148.00 Cr., marking an increase of 49.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 178.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 153.00 Cr. (Mar 2024) to 178.00 Cr., marking an increase of 25.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 844.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 743.00 Cr. (Mar 2024) to 844.00 Cr., marking an increase of 101.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 208.00 Cr.. The value appears strong and on an upward trend. It has increased from 182.00 Cr. (Mar 2024) to 208.00 Cr., marking an increase of 26.00 Cr..
- For CWIP, as of Mar 2025, the value is 113.00 Cr.. The value appears strong and on an upward trend. It has increased from 97.00 Cr. (Mar 2024) to 113.00 Cr., marking an increase of 16.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 522.00 Cr.. The value appears strong and on an upward trend. It has increased from 465.00 Cr. (Mar 2024) to 522.00 Cr., marking an increase of 57.00 Cr..
- For Total Assets, as of Mar 2025, the value is 844.00 Cr.. The value appears strong and on an upward trend. It has increased from 743.00 Cr. (Mar 2024) to 844.00 Cr., marking an increase of 101.00 Cr..
Notably, the Reserves (470.00 Cr.) exceed the Borrowings (148.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -94.00 | -55.00 | -50.00 | -59.00 | -58.00 | -51.00 | -41.00 | 16.00 | 12.00 | -23.00 | -25.00 | -75.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 91 | 70 | 86 | 75 | 88 | 94 | 89 | 97 | 108 | 126 | 125 |
| Inventory Days | 103 | 78 | 119 | 122 | 138 | 129 | 154 | 121 | 202 | 133 | 126 | 153 |
| Days Payable | 69 | 119 | 115 | 95 | 118 | 90 | 95 | 104 | 84 | 89 | 103 | 108 |
| Cash Conversion Cycle | 101 | 50 | 74 | 113 | 96 | 127 | 153 | 106 | 215 | 152 | 149 | 170 |
| Working Capital Days | 45 | 9 | 34 | 43 | 60 | 70 | 79 | 81 | 158 | 139 | 131 | 113 |
| ROCE % | 14% | 14% | 14% | 19% | 14% | 16% | 14% | 30% | 21% | 8% | 14% | 10% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Healthcare Fund | 101,067 | 1.41 | 2.28 | 101,067 | 2025-04-22 17:25:28 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 251 | 0.07 | 0.01 | 251 | 2025-04-22 17:25:28 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 7.99 | 10.57 | 5.65 | 13.77 | 14.24 |
| Diluted EPS (Rs.) | 7.99 | 10.57 | 5.65 | 13.77 | 14.24 |
| Cash EPS (Rs.) | 11.21 | 13.24 | 8.29 | 14.96 | 16.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 107.35 | 101.90 | 91.11 | 88.40 | 56.65 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 107.35 | 101.90 | 91.11 | 88.40 | 56.65 |
| Revenue From Operations / Share (Rs.) | 130.39 | 127.48 | 114.29 | 99.05 | 113.71 |
| PBDIT / Share (Rs.) | 15.92 | 18.47 | 11.38 | 20.33 | 23.07 |
| PBIT / Share (Rs.) | 12.69 | 15.79 | 8.74 | 18.02 | 20.71 |
| PBT / Share (Rs.) | 10.76 | 14.01 | 7.48 | 16.96 | 19.27 |
| Net Profit / Share (Rs.) | 7.98 | 10.57 | 5.65 | 12.66 | 14.24 |
| NP After MI And SOA / Share (Rs.) | 7.98 | 10.57 | 5.65 | 12.66 | 14.24 |
| PBDIT Margin (%) | 12.21 | 14.48 | 9.95 | 20.52 | 20.28 |
| PBIT Margin (%) | 9.73 | 12.38 | 7.64 | 18.19 | 18.21 |
| PBT Margin (%) | 8.25 | 10.99 | 6.54 | 17.12 | 16.94 |
| Net Profit Margin (%) | 6.12 | 8.29 | 4.94 | 12.78 | 12.52 |
| NP After MI And SOA Margin (%) | 6.12 | 8.29 | 4.94 | 12.78 | 12.52 |
| Return on Networth / Equity (%) | 7.43 | 10.37 | 6.19 | 14.32 | 25.14 |
| Return on Capital Employeed (%) | 11.04 | 14.51 | 8.91 | 18.91 | 32.14 |
| Return On Assets (%) | 4.56 | 6.85 | 4.19 | 9.99 | 14.02 |
| Long Term Debt / Equity (X) | 0.03 | 0.03 | 0.04 | 0.04 | 0.08 |
| Total Debt / Equity (X) | 0.28 | 0.20 | 0.17 | 0.17 | 0.26 |
| Asset Turnover Ratio (%) | 0.79 | 0.88 | 0.87 | 0.45 | 0.64 |
| Current Ratio (X) | 1.76 | 2.08 | 2.25 | 2.74 | 1.72 |
| Quick Ratio (X) | 1.18 | 1.44 | 1.52 | 1.75 | 1.10 |
| Inventory Turnover Ratio (X) | 4.09 | 2.93 | 2.29 | 1.82 | 1.81 |
| Dividend Payout Ratio (NP) (%) | 37.51 | 28.38 | 53.10 | 10.62 | 10.53 |
| Dividend Payout Ratio (CP) (%) | 26.71 | 22.65 | 36.20 | 8.99 | 9.03 |
| Earning Retention Ratio (%) | 62.49 | 71.62 | 46.90 | 89.38 | 89.47 |
| Cash Earning Retention Ratio (%) | 73.29 | 77.35 | 63.80 | 91.01 | 90.97 |
| Interest Coverage Ratio (X) | 8.23 | 10.36 | 9.02 | 19.15 | 15.99 |
| Interest Coverage Ratio (Post Tax) (X) | 5.13 | 6.93 | 5.48 | 12.93 | 10.87 |
| Enterprise Value (Cr.) | 967.40 | 1330.79 | 595.14 | 1372.72 | 511.32 |
| EV / Net Operating Revenue (X) | 1.54 | 2.17 | 1.08 | 2.87 | 1.04 |
| EV / EBITDA (X) | 12.58 | 14.95 | 10.85 | 14.01 | 5.13 |
| MarketCap / Net Operating Revenue (X) | 1.34 | 2.03 | 0.96 | 2.84 | 0.92 |
| Retention Ratios (%) | 62.48 | 71.61 | 46.89 | 89.37 | 89.46 |
| Price / BV (X) | 1.63 | 2.54 | 1.21 | 3.19 | 1.85 |
| Price / Net Operating Revenue (X) | 1.34 | 2.03 | 0.96 | 2.84 | 0.92 |
| EarningsYield | 0.04 | 0.04 | 0.05 | 0.04 | 0.13 |
After reviewing the key financial ratios for Kopran Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 7.99. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.99, marking a decrease of 2.58.
- For Diluted EPS (Rs.), as of Mar 25, the value is 7.99. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.99, marking a decrease of 2.58.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.21. This value is within the healthy range. It has decreased from 13.24 (Mar 24) to 11.21, marking a decrease of 2.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 107.35. It has increased from 101.90 (Mar 24) to 107.35, marking an increase of 5.45.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 107.35. It has increased from 101.90 (Mar 24) to 107.35, marking an increase of 5.45.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 130.39. It has increased from 127.48 (Mar 24) to 130.39, marking an increase of 2.91.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 15.92. This value is within the healthy range. It has decreased from 18.47 (Mar 24) to 15.92, marking a decrease of 2.55.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.69. This value is within the healthy range. It has decreased from 15.79 (Mar 24) to 12.69, marking a decrease of 3.10.
- For PBT / Share (Rs.), as of Mar 25, the value is 10.76. This value is within the healthy range. It has decreased from 14.01 (Mar 24) to 10.76, marking a decrease of 3.25.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 7.98. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.98, marking a decrease of 2.59.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.98. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.98, marking a decrease of 2.59.
- For PBDIT Margin (%), as of Mar 25, the value is 12.21. This value is within the healthy range. It has decreased from 14.48 (Mar 24) to 12.21, marking a decrease of 2.27.
- For PBIT Margin (%), as of Mar 25, the value is 9.73. This value is below the healthy minimum of 10. It has decreased from 12.38 (Mar 24) to 9.73, marking a decrease of 2.65.
- For PBT Margin (%), as of Mar 25, the value is 8.25. This value is below the healthy minimum of 10. It has decreased from 10.99 (Mar 24) to 8.25, marking a decrease of 2.74.
- For Net Profit Margin (%), as of Mar 25, the value is 6.12. This value is within the healthy range. It has decreased from 8.29 (Mar 24) to 6.12, marking a decrease of 2.17.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.12. This value is below the healthy minimum of 8. It has decreased from 8.29 (Mar 24) to 6.12, marking a decrease of 2.17.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.43. This value is below the healthy minimum of 15. It has decreased from 10.37 (Mar 24) to 7.43, marking a decrease of 2.94.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.04. This value is within the healthy range. It has decreased from 14.51 (Mar 24) to 11.04, marking a decrease of 3.47.
- For Return On Assets (%), as of Mar 25, the value is 4.56. This value is below the healthy minimum of 5. It has decreased from 6.85 (Mar 24) to 4.56, marking a decrease of 2.29.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.28. This value is within the healthy range. It has increased from 0.20 (Mar 24) to 0.28, marking an increase of 0.08.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.79. It has decreased from 0.88 (Mar 24) to 0.79, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 1.76. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.76, marking a decrease of 0.32.
- For Quick Ratio (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has decreased from 1.44 (Mar 24) to 1.18, marking a decrease of 0.26.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.09. This value is within the healthy range. It has increased from 2.93 (Mar 24) to 4.09, marking an increase of 1.16.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 37.51. This value is within the healthy range. It has increased from 28.38 (Mar 24) to 37.51, marking an increase of 9.13.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 26.71. This value is within the healthy range. It has increased from 22.65 (Mar 24) to 26.71, marking an increase of 4.06.
- For Earning Retention Ratio (%), as of Mar 25, the value is 62.49. This value is within the healthy range. It has decreased from 71.62 (Mar 24) to 62.49, marking a decrease of 9.13.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 73.29. This value exceeds the healthy maximum of 70. It has decreased from 77.35 (Mar 24) to 73.29, marking a decrease of 4.06.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.23. This value is within the healthy range. It has decreased from 10.36 (Mar 24) to 8.23, marking a decrease of 2.13.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.13. This value is within the healthy range. It has decreased from 6.93 (Mar 24) to 5.13, marking a decrease of 1.80.
- For Enterprise Value (Cr.), as of Mar 25, the value is 967.40. It has decreased from 1,330.79 (Mar 24) to 967.40, marking a decrease of 363.39.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.54. This value is within the healthy range. It has decreased from 2.17 (Mar 24) to 1.54, marking a decrease of 0.63.
- For EV / EBITDA (X), as of Mar 25, the value is 12.58. This value is within the healthy range. It has decreased from 14.95 (Mar 24) to 12.58, marking a decrease of 2.37.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.34, marking a decrease of 0.69.
- For Retention Ratios (%), as of Mar 25, the value is 62.48. This value is within the healthy range. It has decreased from 71.61 (Mar 24) to 62.48, marking a decrease of 9.13.
- For Price / BV (X), as of Mar 25, the value is 1.63. This value is within the healthy range. It has decreased from 2.54 (Mar 24) to 1.63, marking a decrease of 0.91.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.34, marking a decrease of 0.69.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Kopran Ltd:
- Net Profit Margin: 6.12%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.04% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.43% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.13
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.18
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 41.3 (Industry average Stock P/E: 53.76)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.28
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.12%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Parijat House, 1076, Dr. E. Moses Road, Mumbai Maharashtra 400018 | investors@kopran.com http://www.kopran.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Susheel G Somani | Chairman |
| Mr. Surendra Somani | Executive Vice Chairman |
| Mr. Adarsh Somani | Director |
| Mr. Varun Somani | Director |
| Dr. Siddhan Subramanian | Independent Director |
| Dr. Sunita Banerji | Independent Director |
| Mrs. Mamta Biyani | Independent Director |
| Mr. Narayan Atal | Independent Director |
FAQ
What is the intrinsic value of Kopran Ltd?
Kopran Ltd's intrinsic value (as of 12 November 2025) is 267.75 which is 77.32% higher the current market price of 151.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 728 Cr. market cap, FY2025-2026 high/low of 294/148, reserves of ₹470 Cr, and liabilities of 844 Cr.
What is the Market Cap of Kopran Ltd?
The Market Cap of Kopran Ltd is 728 Cr..
What is the current Stock Price of Kopran Ltd as on 12 November 2025?
The current stock price of Kopran Ltd as on 12 November 2025 is 151.
What is the High / Low of Kopran Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Kopran Ltd stocks is 294/148.
What is the Stock P/E of Kopran Ltd?
The Stock P/E of Kopran Ltd is 41.3.
What is the Book Value of Kopran Ltd?
The Book Value of Kopran Ltd is 104.
What is the Dividend Yield of Kopran Ltd?
The Dividend Yield of Kopran Ltd is 1.99 %.
What is the ROCE of Kopran Ltd?
The ROCE of Kopran Ltd is 9.75 %.
What is the ROE of Kopran Ltd?
The ROE of Kopran Ltd is 7.64 %.
What is the Face Value of Kopran Ltd?
The Face Value of Kopran Ltd is 10.0.